Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
***** Acces problem to record *****\

Identifieur interne : 000264 ( Pmc/Corpus ); précédent : 0002639; suivant : 0002650 ***** probable Xml problem with record *****

Links to Exploration step


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus</title>
<author>
<name sortKey="Ba, Lei" sort="Ba, Lei" uniqKey="Ba L" first="Lei" last="Ba">Lei Ba</name>
<affiliation>
<nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Yi, Christopher E" sort="Yi, Christopher E" uniqKey="Yi C" first="Christopher E." last="Yi">Christopher E. Yi</name>
<affiliation>
<nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Zhang, Linqi" sort="Zhang, Linqi" uniqKey="Zhang L" first="Linqi" last="Zhang">Linqi Zhang</name>
<affiliation>
<nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Ho, David D" sort="Ho, David D" uniqKey="Ho D" first="David D." last="Ho">David D. Ho</name>
<affiliation>
<nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Chen, Zhiwei" sort="Chen, Zhiwei" uniqKey="Chen Z" first="Zhiwei" last="Chen">Zhiwei Chen</name>
<affiliation>
<nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">17581748</idno>
<idno type="pmc">7079952</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079952</idno>
<idno type="RBID">PMC:7079952</idno>
<idno type="doi">10.1007/s00253-007-1073-y</idno>
<date when="2007">2007</date>
<idno type="wicri:Area/Pmc/Corpus">000264</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000264</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus</title>
<author>
<name sortKey="Ba, Lei" sort="Ba, Lei" uniqKey="Ba L" first="Lei" last="Ba">Lei Ba</name>
<affiliation>
<nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Yi, Christopher E" sort="Yi, Christopher E" uniqKey="Yi C" first="Christopher E." last="Yi">Christopher E. Yi</name>
<affiliation>
<nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Zhang, Linqi" sort="Zhang, Linqi" uniqKey="Zhang L" first="Linqi" last="Zhang">Linqi Zhang</name>
<affiliation>
<nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Ho, David D" sort="Ho, David D" uniqKey="Ho D" first="David D." last="Ho">David D. Ho</name>
<affiliation>
<nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Chen, Zhiwei" sort="Chen, Zhiwei" uniqKey="Chen Z" first="Zhiwei" last="Chen">Zhiwei Chen</name>
<affiliation>
<nlm:aff id="Aff1"></nlm:aff>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Applied Microbiology and Biotechnology</title>
<idno type="ISSN">0175-7598</idno>
<idno type="eISSN">1432-0614</idno>
<imprint>
<date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>Severe acute respiratory syndrome (SARS) is caused by a novel coronavirus (CoV), SARS-CoV. In previous studies, we showed that a SARS-CoV spike (S) glycoprotein-based modified vaccinia Ankara (MVA-S) vaccine could induce strong neutralizing antibody (Nab) response which might have played a critical role in protecting Chinese rhesus monkeys from the pathogenic viral challenge. To date, however, it remains unknown what the minimal level of Nab is required to achieve sterile immunity in humans. It is therefore important to explore techniques to maximize the level of Nab response in vivo. Here, we evaluate various vaccination regimens using combinations of DNA-S, MVA-S, and adenovirus type 5 (Ad5-S) vaccines. We show that in vaccinated mice and rabbits, a heterologous MVA-S prime with Ad5-S boost regimen induces the highest and most persistent level of Nab response when compared with other combinations. Interestingly, the initial level of Nab after prime does not necessarily predict the magnitude of the secondary response after the boost. Thus, our data provides a promising optimal regimen for vaccine development in humans against SARS-CoV infection.</p>
</div>
</front>
<back>
<div1 type="bibliography">
<listBibl>
<biblStruct>
<analytic>
<author>
<name sortKey="Amara, Rr" uniqKey="Amara R">RR Amara</name>
</author>
<author>
<name sortKey="Villinger, F" uniqKey="Villinger F">F Villinger</name>
</author>
<author>
<name sortKey="Altman, Jd" uniqKey="Altman J">JD Altman</name>
</author>
<author>
<name sortKey="Lydy, Sl" uniqKey="Lydy S">SL Lydy</name>
</author>
<author>
<name sortKey="O Eil, Sp" uniqKey="O Eil S">SP O’Neil</name>
</author>
<author>
<name sortKey="Staprans, Si" uniqKey="Staprans S">SI Staprans</name>
</author>
<author>
<name sortKey="Montefiori, Dc" uniqKey="Montefiori D">DC Montefiori</name>
</author>
<author>
<name sortKey="Xu, Y" uniqKey="Xu Y">Y Xu</name>
</author>
<author>
<name sortKey="Herndon, Jg" uniqKey="Herndon J">JG Herndon</name>
</author>
<author>
<name sortKey="Wyatt, Ls" uniqKey="Wyatt L">LS Wyatt</name>
</author>
<author>
<name sortKey="Candido, Ma" uniqKey="Candido M">MA Candido</name>
</author>
<author>
<name sortKey="Kozyr, Nl" uniqKey="Kozyr N">NL Kozyr</name>
</author>
<author>
<name sortKey="Earl, Pl" uniqKey="Earl P">PL Earl</name>
</author>
<author>
<name sortKey="Smith, Jm" uniqKey="Smith J">JM Smith</name>
</author>
<author>
<name sortKey="Ma, Hl" uniqKey="Ma H">HL Ma</name>
</author>
<author>
<name sortKey="Grimm, Bd" uniqKey="Grimm B">BD Grimm</name>
</author>
<author>
<name sortKey="Hulsey, Ml" uniqKey="Hulsey M">ML Hulsey</name>
</author>
<author>
<name sortKey="Miller, J" uniqKey="Miller J">J Miller</name>
</author>
<author>
<name sortKey="Mcclure, Hm" uniqKey="Mcclure H">HM McClure</name>
</author>
<author>
<name sortKey="Mcnicholl, Jm" uniqKey="Mcnicholl J">JM McNicholl</name>
</author>
<author>
<name sortKey="Moss, B" uniqKey="Moss B">B Moss</name>
</author>
<author>
<name sortKey="Robinson, Hl" uniqKey="Robinson H">HL Robinson</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Bisht, H" uniqKey="Bisht H">H Bisht</name>
</author>
<author>
<name sortKey="Roberts, A" uniqKey="Roberts A">A Roberts</name>
</author>
<author>
<name sortKey="Vogel, L" uniqKey="Vogel L">L Vogel</name>
</author>
<author>
<name sortKey="Bukreyev, A" uniqKey="Bukreyev A">A Bukreyev</name>
</author>
<author>
<name sortKey="Collins, Pl" uniqKey="Collins P">PL Collins</name>
</author>
<author>
<name sortKey="Murphy, Br" uniqKey="Murphy B">BR Murphy</name>
</author>
<author>
<name sortKey="Subbarao, K" uniqKey="Subbarao K">K Subbarao</name>
</author>
<author>
<name sortKey="Moss, B" uniqKey="Moss B">B Moss</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Bisht, H" uniqKey="Bisht H">H Bisht</name>
</author>
<author>
<name sortKey="Roberts, A" uniqKey="Roberts A">A Roberts</name>
</author>
<author>
<name sortKey="Vogel, L" uniqKey="Vogel L">L Vogel</name>
</author>
<author>
<name sortKey="Subbarao, K" uniqKey="Subbarao K">K Subbarao</name>
</author>
<author>
<name sortKey="Moss, B" uniqKey="Moss B">B Moss</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Bukreyev, A" uniqKey="Bukreyev A">A Bukreyev</name>
</author>
<author>
<name sortKey="Lamirande, Ew" uniqKey="Lamirande E">EW Lamirande</name>
</author>
<author>
<name sortKey="Buchholz, Uj" uniqKey="Buchholz U">UJ Buchholz</name>
</author>
<author>
<name sortKey="Vogel, Ln" uniqKey="Vogel L">LN Vogel</name>
</author>
<author>
<name sortKey="Elkins, Wr" uniqKey="Elkins W">WR Elkins</name>
</author>
<author>
<name sortKey="St Claire, M" uniqKey="St Claire M">M St Claire</name>
</author>
<author>
<name sortKey="Murphy, Br" uniqKey="Murphy B">BR Murphy</name>
</author>
<author>
<name sortKey="Subbarao, K" uniqKey="Subbarao K">K Subbarao</name>
</author>
<author>
<name sortKey="Collins, Pl" uniqKey="Collins P">PL Collins</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Casimiro, Dr" uniqKey="Casimiro D">DR Casimiro</name>
</author>
<author>
<name sortKey="Bett, Aj" uniqKey="Bett A">AJ Bett</name>
</author>
<author>
<name sortKey="Fu, Tm" uniqKey="Fu T">TM Fu</name>
</author>
<author>
<name sortKey="Davies, Me" uniqKey="Davies M">ME Davies</name>
</author>
<author>
<name sortKey="Tang, A" uniqKey="Tang A">A Tang</name>
</author>
<author>
<name sortKey="Wilson, Ka" uniqKey="Wilson K">KA Wilson</name>
</author>
<author>
<name sortKey="Chen, M" uniqKey="Chen M">M Chen</name>
</author>
<author>
<name sortKey="Long, R" uniqKey="Long R">R Long</name>
</author>
<author>
<name sortKey="Mckelvey, T" uniqKey="Mckelvey T">T McKelvey</name>
</author>
<author>
<name sortKey="Chastain, M" uniqKey="Chastain M">M Chastain</name>
</author>
<author>
<name sortKey="Gurunathan, S" uniqKey="Gurunathan S">S Gurunathan</name>
</author>
<author>
<name sortKey="Tartaglia, J" uniqKey="Tartaglia J">J Tartaglia</name>
</author>
<author>
<name sortKey="Emini, Ea" uniqKey="Emini E">EA Emini</name>
</author>
<author>
<name sortKey="Shiver, J" uniqKey="Shiver J">J Shiver</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Chen, Z" uniqKey="Chen Z">Z Chen</name>
</author>
<author>
<name sortKey="Zhang, L" uniqKey="Zhang L">L Zhang</name>
</author>
<author>
<name sortKey="Qin, C" uniqKey="Qin C">C Qin</name>
</author>
<author>
<name sortKey="Ba, L" uniqKey="Ba L">L Ba</name>
</author>
<author>
<name sortKey="Yi, Ce" uniqKey="Yi C">CE Yi</name>
</author>
<author>
<name sortKey="Zhang, F" uniqKey="Zhang F">F Zhang</name>
</author>
<author>
<name sortKey="Wei, Q" uniqKey="Wei Q">Q Wei</name>
</author>
<author>
<name sortKey="He, T" uniqKey="He T">T He</name>
</author>
<author>
<name sortKey="Yu, W" uniqKey="Yu W">W Yu</name>
</author>
<author>
<name sortKey="Yu, J" uniqKey="Yu J">J Yu</name>
</author>
<author>
<name sortKey="Gao, H" uniqKey="Gao H">H Gao</name>
</author>
<author>
<name sortKey="Tu, X" uniqKey="Tu X">X Tu</name>
</author>
<author>
<name sortKey="Gettie, A" uniqKey="Gettie A">A Gettie</name>
</author>
<author>
<name sortKey="Farzan, M" uniqKey="Farzan M">M Farzan</name>
</author>
<author>
<name sortKey="Yuen, Ky" uniqKey="Yuen K">KY Yuen</name>
</author>
<author>
<name sortKey="Ho, Dd" uniqKey="Ho D">DD Ho</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Degano, P" uniqKey="Degano P">P Degano</name>
</author>
<author>
<name sortKey="Schneider, J" uniqKey="Schneider J">J Schneider</name>
</author>
<author>
<name sortKey="Hannan, Cm" uniqKey="Hannan C">CM Hannan</name>
</author>
<author>
<name sortKey="Gilbert, Sc" uniqKey="Gilbert S">SC Gilbert</name>
</author>
<author>
<name sortKey="Hill, Av" uniqKey="Hill A">AV Hill</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Deming, D" uniqKey="Deming D">D Deming</name>
</author>
<author>
<name sortKey="Sheahan, T" uniqKey="Sheahan T">T Sheahan</name>
</author>
<author>
<name sortKey="Heise, M" uniqKey="Heise M">M Heise</name>
</author>
<author>
<name sortKey="Yount, B" uniqKey="Yount B">B Yount</name>
</author>
<author>
<name sortKey="Davis, N" uniqKey="Davis N">N Davis</name>
</author>
<author>
<name sortKey="Sims, A" uniqKey="Sims A">A Sims</name>
</author>
<author>
<name sortKey="Suthar, M" uniqKey="Suthar M">M Suthar</name>
</author>
<author>
<name sortKey="Harkema, J" uniqKey="Harkema J">J Harkema</name>
</author>
<author>
<name sortKey="Whitmore, A" uniqKey="Whitmore A">A Whitmore</name>
</author>
<author>
<name sortKey="Pickles, R" uniqKey="Pickles R">R Pickles</name>
</author>
<author>
<name sortKey="West, A" uniqKey="West A">A West</name>
</author>
<author>
<name sortKey="Donaldson, E" uniqKey="Donaldson E">E Donaldson</name>
</author>
<author>
<name sortKey="Curtis, K" uniqKey="Curtis K">K Curtis</name>
</author>
<author>
<name sortKey="Johnston, R" uniqKey="Johnston R">R Johnston</name>
</author>
<author>
<name sortKey="Baric, R" uniqKey="Baric R">R Baric</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Drosten, C" uniqKey="Drosten C">C Drosten</name>
</author>
<author>
<name sortKey="Preiser, W" uniqKey="Preiser W">W Preiser</name>
</author>
<author>
<name sortKey="Gunther, S" uniqKey="Gunther S">S Gunther</name>
</author>
<author>
<name sortKey="Schmitz, H" uniqKey="Schmitz H">H Schmitz</name>
</author>
<author>
<name sortKey="Doerr, Hw" uniqKey="Doerr H">HW Doerr</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Gao, W" uniqKey="Gao W">W Gao</name>
</author>
<author>
<name sortKey="Tamin, A" uniqKey="Tamin A">A Tamin</name>
</author>
<author>
<name sortKey="Soloff, A" uniqKey="Soloff A">A Soloff</name>
</author>
<author>
<name sortKey="D Iuto, L" uniqKey="D Iuto L">L D’Aiuto</name>
</author>
<author>
<name sortKey="Nwanegbo, E" uniqKey="Nwanegbo E">E Nwanegbo</name>
</author>
<author>
<name sortKey="Robbins, Pd" uniqKey="Robbins P">PD Robbins</name>
</author>
<author>
<name sortKey="Bellini, Wj" uniqKey="Bellini W">WJ Bellini</name>
</author>
<author>
<name sortKey="Barratt Boyes, S" uniqKey="Barratt Boyes S">S Barratt-Boyes</name>
</author>
<author>
<name sortKey="Gambotto, A" uniqKey="Gambotto A">A Gambotto</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Gilbert, Sc" uniqKey="Gilbert S">SC Gilbert</name>
</author>
<author>
<name sortKey="Schneider, J" uniqKey="Schneider J">J Schneider</name>
</author>
<author>
<name sortKey="Hannan, Cm" uniqKey="Hannan C">CM Hannan</name>
</author>
<author>
<name sortKey="Hu, Jt" uniqKey="Hu J">JT Hu</name>
</author>
<author>
<name sortKey="Plebanski, M" uniqKey="Plebanski M">M Plebanski</name>
</author>
<author>
<name sortKey="Sinden, R" uniqKey="Sinden R">R Sinden</name>
</author>
<author>
<name sortKey="Hill, Av" uniqKey="Hill A">AV Hill</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="He, Y" uniqKey="He Y">Y He</name>
</author>
<author>
<name sortKey="Lu, H" uniqKey="Lu H">H Lu</name>
</author>
<author>
<name sortKey="Siddiqui, P" uniqKey="Siddiqui P">P Siddiqui</name>
</author>
<author>
<name sortKey="Zhou, Y" uniqKey="Zhou Y">Y Zhou</name>
</author>
<author>
<name sortKey="Jiang, S" uniqKey="Jiang S">S Jiang</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Horton, H" uniqKey="Horton H">H Horton</name>
</author>
<author>
<name sortKey="Vogel, Tu" uniqKey="Vogel T">TU Vogel</name>
</author>
<author>
<name sortKey="Carter, Dk" uniqKey="Carter D">DK Carter</name>
</author>
<author>
<name sortKey="Vielhuber, K" uniqKey="Vielhuber K">K Vielhuber</name>
</author>
<author>
<name sortKey="Fuller, Dh" uniqKey="Fuller D">DH Fuller</name>
</author>
<author>
<name sortKey="Shipley, T" uniqKey="Shipley T">T Shipley</name>
</author>
<author>
<name sortKey="Fuller, Jt" uniqKey="Fuller J">JT Fuller</name>
</author>
<author>
<name sortKey="Kunstman, Kj" uniqKey="Kunstman K">KJ Kunstman</name>
</author>
<author>
<name sortKey="Sutter, G" uniqKey="Sutter G">G Sutter</name>
</author>
<author>
<name sortKey="Montefiori, Dc" uniqKey="Montefiori D">DC Montefiori</name>
</author>
<author>
<name sortKey="Erfle, V" uniqKey="Erfle V">V Erfle</name>
</author>
<author>
<name sortKey="Desrosiers, Rc" uniqKey="Desrosiers R">RC Desrosiers</name>
</author>
<author>
<name sortKey="Wilson, N" uniqKey="Wilson N">N Wilson</name>
</author>
<author>
<name sortKey="Picker, Lj" uniqKey="Picker L">LJ Picker</name>
</author>
<author>
<name sortKey="Wolinsky, Sm" uniqKey="Wolinsky S">SM Wolinsky</name>
</author>
<author>
<name sortKey="Wang, C" uniqKey="Wang C">C Wang</name>
</author>
<author>
<name sortKey="Allison, Db" uniqKey="Allison D">DB Allison</name>
</author>
<author>
<name sortKey="Watkins, Di" uniqKey="Watkins D">DI Watkins</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ksiazek, Tg" uniqKey="Ksiazek T">TG Ksiazek</name>
</author>
<author>
<name sortKey="Erdman, D" uniqKey="Erdman D">D Erdman</name>
</author>
<author>
<name sortKey="Goldsmith, Cs" uniqKey="Goldsmith C">CS Goldsmith</name>
</author>
<author>
<name sortKey="Zaki, Sr" uniqKey="Zaki S">SR Zaki</name>
</author>
<author>
<name sortKey="Peret, T" uniqKey="Peret T">T Peret</name>
</author>
<author>
<name sortKey="Emery, S" uniqKey="Emery S">S Emery</name>
</author>
<author>
<name sortKey="Tong, S" uniqKey="Tong S">S Tong</name>
</author>
<author>
<name sortKey="Urbani, C" uniqKey="Urbani C">C Urbani</name>
</author>
<author>
<name sortKey="Comer, Ja" uniqKey="Comer J">JA Comer</name>
</author>
<author>
<name sortKey="Lim, W" uniqKey="Lim W">W Lim</name>
</author>
<author>
<name sortKey="Rollin, Pe" uniqKey="Rollin P">PE Rollin</name>
</author>
<author>
<name sortKey="Dowell, Sf" uniqKey="Dowell S">SF Dowell</name>
</author>
<author>
<name sortKey="Ling, Ae" uniqKey="Ling A">AE Ling</name>
</author>
<author>
<name sortKey="Humphrey, Cd" uniqKey="Humphrey C">CD Humphrey</name>
</author>
<author>
<name sortKey="Shieh, Wj" uniqKey="Shieh W">WJ Shieh</name>
</author>
<author>
<name sortKey="Guarner, J" uniqKey="Guarner J">J Guarner</name>
</author>
<author>
<name sortKey="Paddock, Cd" uniqKey="Paddock C">CD Paddock</name>
</author>
<author>
<name sortKey="Rota, P" uniqKey="Rota P">P Rota</name>
</author>
<author>
<name sortKey="Fields, B" uniqKey="Fields B">B Fields</name>
</author>
<author>
<name sortKey="Derisi, J" uniqKey="Derisi J">J DeRisi</name>
</author>
<author>
<name sortKey="Yang, Jy" uniqKey="Yang J">JY Yang</name>
</author>
<author>
<name sortKey="Cox, N" uniqKey="Cox N">N Cox</name>
</author>
<author>
<name sortKey="Hughes, Jm" uniqKey="Hughes J">JM Hughes</name>
</author>
<author>
<name sortKey="Leduc, Jw" uniqKey="Leduc J">JW LeDuc</name>
</author>
<author>
<name sortKey="Bellini, Wj" uniqKey="Bellini W">WJ Bellini</name>
</author>
<author>
<name sortKey="Anderson, Lj" uniqKey="Anderson L">LJ Anderson</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Kuiken, T" uniqKey="Kuiken T">T Kuiken</name>
</author>
<author>
<name sortKey="Fouchier, Ra" uniqKey="Fouchier R">RA Fouchier</name>
</author>
<author>
<name sortKey="Schutten, M" uniqKey="Schutten M">M Schutten</name>
</author>
<author>
<name sortKey="Rimmelzwaan, Gf" uniqKey="Rimmelzwaan G">GF Rimmelzwaan</name>
</author>
<author>
<name sortKey="Van Amerongen, G" uniqKey="Van Amerongen G">G van Amerongen</name>
</author>
<author>
<name sortKey="Van Riel, D" uniqKey="Van Riel D">D van Riel</name>
</author>
<author>
<name sortKey="Laman, Jd" uniqKey="Laman J">JD Laman</name>
</author>
<author>
<name sortKey="De Jong, T" uniqKey="De Jong T">T de Jong</name>
</author>
<author>
<name sortKey="Van Doornum, G" uniqKey="Van Doornum G">G van Doornum</name>
</author>
<author>
<name sortKey="Lim, W" uniqKey="Lim W">W Lim</name>
</author>
<author>
<name sortKey="Ling, Ae" uniqKey="Ling A">AE Ling</name>
</author>
<author>
<name sortKey="Chan, Pk" uniqKey="Chan P">PK Chan</name>
</author>
<author>
<name sortKey="Tam, Js" uniqKey="Tam J">JS Tam</name>
</author>
<author>
<name sortKey="Zambon, Mc" uniqKey="Zambon M">MC Zambon</name>
</author>
<author>
<name sortKey="Gopal, R" uniqKey="Gopal R">R Gopal</name>
</author>
<author>
<name sortKey="Drosten, C" uniqKey="Drosten C">C Drosten</name>
</author>
<author>
<name sortKey="Van Der Werf, S" uniqKey="Van Der Werf S">S van der Werf</name>
</author>
<author>
<name sortKey="Escriou, N" uniqKey="Escriou N">N Escriou</name>
</author>
<author>
<name sortKey="Manuguerra, Jc" uniqKey="Manuguerra J">JC Manuguerra</name>
</author>
<author>
<name sortKey="Stohr, K" uniqKey="Stohr K">K Stohr</name>
</author>
<author>
<name sortKey="Peiris, Js" uniqKey="Peiris J">JS Peiris</name>
</author>
<author>
<name sortKey="Osterhaus, Ad" uniqKey="Osterhaus A">AD Osterhaus</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Li, W" uniqKey="Li W">W. Li</name>
</author>
<author>
<name sortKey="Moore, M J" uniqKey="Moore M">M.J. Moore</name>
</author>
<author>
<name sortKey="Vasilieva, N" uniqKey="Vasilieva N">N. Vasilieva</name>
</author>
<author>
<name sortKey="Sui, J" uniqKey="Sui J">J. Sui</name>
</author>
<author>
<name sortKey="Wong, S K" uniqKey="Wong S">S.K. Wong</name>
</author>
<author>
<name sortKey="Berne, M A" uniqKey="Berne M">M.A. Berne</name>
</author>
<author>
<name sortKey="Somasundaran, M" uniqKey="Somasundaran M">M. Somasundaran</name>
</author>
<author>
<name sortKey="Sullivan, J L" uniqKey="Sullivan J">J.L. Sullivan</name>
</author>
<author>
<name sortKey="Luzuriaga, K" uniqKey="Luzuriaga K">K. Luzuriaga</name>
</author>
<author>
<name sortKey="Greenough, T C" uniqKey="Greenough T">T.C. Greenough</name>
</author>
<author>
<name sortKey="Choe, H" uniqKey="Choe H">H. Choe</name>
</author>
<author>
<name sortKey="Farzan, M" uniqKey="Farzan M">M. Farzan</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Li, F" uniqKey="Li F">F Li</name>
</author>
<author>
<name sortKey="Li, W" uniqKey="Li W">W Li</name>
</author>
<author>
<name sortKey="Farzan, M" uniqKey="Farzan M">M Farzan</name>
</author>
<author>
<name sortKey="Harrison, Sc" uniqKey="Harrison S">SC Harrison</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Liu, L" uniqKey="Liu L">L Liu</name>
</author>
<author>
<name sortKey="Fang, Q" uniqKey="Fang Q">Q Fang</name>
</author>
<author>
<name sortKey="Deng, F" uniqKey="Deng F">F Deng</name>
</author>
<author>
<name sortKey="Wang, H" uniqKey="Wang H">H Wang</name>
</author>
<author>
<name sortKey="Yi, Ce" uniqKey="Yi C">CE Yi</name>
</author>
<author>
<name sortKey="Ba, L" uniqKey="Ba L">L Ba</name>
</author>
<author>
<name sortKey="Yu, W" uniqKey="Yu W">W Yu</name>
</author>
<author>
<name sortKey="Lin, Rd" uniqKey="Lin R">RD Lin</name>
</author>
<author>
<name sortKey="Li, T" uniqKey="Li T">T Li</name>
</author>
<author>
<name sortKey="Hu, Z" uniqKey="Hu Z">Z Hu</name>
</author>
<author>
<name sortKey="Ho, Dd" uniqKey="Ho D">DD Ho</name>
</author>
<author>
<name sortKey="Zhang, L" uniqKey="Zhang L">L Zhang</name>
</author>
<author>
<name sortKey="Chen, Z" uniqKey="Chen Z">Z Chen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Mcconkey, Sj" uniqKey="Mcconkey S">SJ McConkey</name>
</author>
<author>
<name sortKey="Reece, Wh" uniqKey="Reece W">WH Reece</name>
</author>
<author>
<name sortKey="Moorthy, Vs" uniqKey="Moorthy V">VS Moorthy</name>
</author>
<author>
<name sortKey="Webster, D" uniqKey="Webster D">D Webster</name>
</author>
<author>
<name sortKey="Dunachie, S" uniqKey="Dunachie S">S Dunachie</name>
</author>
<author>
<name sortKey="Butcher, G" uniqKey="Butcher G">G Butcher</name>
</author>
<author>
<name sortKey="Vuola, Jm" uniqKey="Vuola J">JM Vuola</name>
</author>
<author>
<name sortKey="Blanchard, Tj" uniqKey="Blanchard T">TJ Blanchard</name>
</author>
<author>
<name sortKey="Gothard, P" uniqKey="Gothard P">P Gothard</name>
</author>
<author>
<name sortKey="Watkins, K" uniqKey="Watkins K">K Watkins</name>
</author>
<author>
<name sortKey="Hannan, Cm" uniqKey="Hannan C">CM Hannan</name>
</author>
<author>
<name sortKey="Everaere, S" uniqKey="Everaere S">S Everaere</name>
</author>
<author>
<name sortKey="Brown, K" uniqKey="Brown K">K Brown</name>
</author>
<author>
<name sortKey="Kester, Ke" uniqKey="Kester K">KE Kester</name>
</author>
<author>
<name sortKey="Cummings, J" uniqKey="Cummings J">J Cummings</name>
</author>
<author>
<name sortKey="Williams, J" uniqKey="Williams J">J Williams</name>
</author>
<author>
<name sortKey="Heppner, Dg" uniqKey="Heppner D">DG Heppner</name>
</author>
<author>
<name sortKey="Pathan, A" uniqKey="Pathan A">A Pathan</name>
</author>
<author>
<name sortKey="Flanagan, K" uniqKey="Flanagan K">K Flanagan</name>
</author>
<author>
<name sortKey="Arulanantham, N" uniqKey="Arulanantham N">N Arulanantham</name>
</author>
<author>
<name sortKey="Roberts, Mt" uniqKey="Roberts M">MT Roberts</name>
</author>
<author>
<name sortKey="Roy, M" uniqKey="Roy M">M Roy</name>
</author>
<author>
<name sortKey="Smith, Gl" uniqKey="Smith G">GL Smith</name>
</author>
<author>
<name sortKey="Schneider, J" uniqKey="Schneider J">J Schneider</name>
</author>
<author>
<name sortKey="Peto, T" uniqKey="Peto T">T Peto</name>
</author>
<author>
<name sortKey="Sinden, Re" uniqKey="Sinden R">RE Sinden</name>
</author>
<author>
<name sortKey="Gilbert, Sc" uniqKey="Gilbert S">SC Gilbert</name>
</author>
<author>
<name sortKey="Hill, Av" uniqKey="Hill A">AV Hill</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Peiris, Js" uniqKey="Peiris J">JS Peiris</name>
</author>
<author>
<name sortKey="Lai, St" uniqKey="Lai S">ST Lai</name>
</author>
<author>
<name sortKey="Poon, Ll" uniqKey="Poon L">LL Poon</name>
</author>
<author>
<name sortKey="Guan, Y" uniqKey="Guan Y">Y Guan</name>
</author>
<author>
<name sortKey="Yam, Ly" uniqKey="Yam L">LY Yam</name>
</author>
<author>
<name sortKey="Lim, W" uniqKey="Lim W">W Lim</name>
</author>
<author>
<name sortKey="Nicholls, J" uniqKey="Nicholls J">J Nicholls</name>
</author>
<author>
<name sortKey="Yee, Wk" uniqKey="Yee W">WK Yee</name>
</author>
<author>
<name sortKey="Yan, Ww" uniqKey="Yan W">WW Yan</name>
</author>
<author>
<name sortKey="Cheung, Mt" uniqKey="Cheung M">MT Cheung</name>
</author>
<author>
<name sortKey="Cheng, Vc" uniqKey="Cheng V">VC Cheng</name>
</author>
<author>
<name sortKey="Chan, Kh" uniqKey="Chan K">KH Chan</name>
</author>
<author>
<name sortKey="Tsang, Dn" uniqKey="Tsang D">DN Tsang</name>
</author>
<author>
<name sortKey="Yung, Rw" uniqKey="Yung R">RW Yung</name>
</author>
<author>
<name sortKey="Ng, Tk" uniqKey="Ng T">TK Ng</name>
</author>
<author>
<name sortKey="Yuen, Ky" uniqKey="Yuen K">KY Yuen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Shiver, Jw" uniqKey="Shiver J">JW Shiver</name>
</author>
<author>
<name sortKey="Fu, Tm" uniqKey="Fu T">TM Fu</name>
</author>
<author>
<name sortKey="Chen, L" uniqKey="Chen L">L Chen</name>
</author>
<author>
<name sortKey="Casimiro, Dr" uniqKey="Casimiro D">DR Casimiro</name>
</author>
<author>
<name sortKey="Davies, Me" uniqKey="Davies M">ME Davies</name>
</author>
<author>
<name sortKey="Evans, Rk" uniqKey="Evans R">RK Evans</name>
</author>
<author>
<name sortKey="Zhang, Zq" uniqKey="Zhang Z">ZQ Zhang</name>
</author>
<author>
<name sortKey="Simon, Aj" uniqKey="Simon A">AJ Simon</name>
</author>
<author>
<name sortKey="Trigona, Wl" uniqKey="Trigona W">WL Trigona</name>
</author>
<author>
<name sortKey="Dubey, Sa" uniqKey="Dubey S">SA Dubey</name>
</author>
<author>
<name sortKey="Huang, L" uniqKey="Huang L">L Huang</name>
</author>
<author>
<name sortKey="Harris, Va" uniqKey="Harris V">VA Harris</name>
</author>
<author>
<name sortKey="Long, Rs" uniqKey="Long R">RS Long</name>
</author>
<author>
<name sortKey="Liang, X" uniqKey="Liang X">X Liang</name>
</author>
<author>
<name sortKey="Handt, L" uniqKey="Handt L">L Handt</name>
</author>
<author>
<name sortKey="Schleif, Wa" uniqKey="Schleif W">WA Schleif</name>
</author>
<author>
<name sortKey="Zhu, L" uniqKey="Zhu L">L Zhu</name>
</author>
<author>
<name sortKey="Freed, Dc" uniqKey="Freed D">DC Freed</name>
</author>
<author>
<name sortKey="Persaud, Nv" uniqKey="Persaud N">NV Persaud</name>
</author>
<author>
<name sortKey="Guan, L" uniqKey="Guan L">L Guan</name>
</author>
<author>
<name sortKey="Punt, Ks" uniqKey="Punt K">KS Punt</name>
</author>
<author>
<name sortKey="Tang, A" uniqKey="Tang A">A Tang</name>
</author>
<author>
<name sortKey="Chen, M" uniqKey="Chen M">M Chen</name>
</author>
<author>
<name sortKey="Wilson, Ka" uniqKey="Wilson K">KA Wilson</name>
</author>
<author>
<name sortKey="Collins, Kb" uniqKey="Collins K">KB Collins</name>
</author>
<author>
<name sortKey="Heidecker, Gj" uniqKey="Heidecker G">GJ Heidecker</name>
</author>
<author>
<name sortKey="Fernandez, Vr" uniqKey="Fernandez V">VR Fernandez</name>
</author>
<author>
<name sortKey="Perry, Hc" uniqKey="Perry H">HC Perry</name>
</author>
<author>
<name sortKey="Joyce, Jg" uniqKey="Joyce J">JG Joyce</name>
</author>
<author>
<name sortKey="Grimm, Km" uniqKey="Grimm K">KM Grimm</name>
</author>
<author>
<name sortKey="Cook, Jc" uniqKey="Cook J">JC Cook</name>
</author>
<author>
<name sortKey="Keller, Pm" uniqKey="Keller P">PM Keller</name>
</author>
<author>
<name sortKey="Kresock, Ds" uniqKey="Kresock D">DS Kresock</name>
</author>
<author>
<name sortKey="Mach, H" uniqKey="Mach H">H Mach</name>
</author>
<author>
<name sortKey="Troutman, Rd" uniqKey="Troutman R">RD Troutman</name>
</author>
<author>
<name sortKey="Isopi, La" uniqKey="Isopi L">LA Isopi</name>
</author>
<author>
<name sortKey="Williams, Dm" uniqKey="Williams D">DM Williams</name>
</author>
<author>
<name sortKey="Xu, Z" uniqKey="Xu Z">Z Xu</name>
</author>
<author>
<name sortKey="Bohannon, Ke" uniqKey="Bohannon K">KE Bohannon</name>
</author>
<author>
<name sortKey="Volkin, Db" uniqKey="Volkin D">DB Volkin</name>
</author>
<author>
<name sortKey="Montefiori, Dc" uniqKey="Montefiori D">DC Montefiori</name>
</author>
<author>
<name sortKey="Miura, A" uniqKey="Miura A">A Miura</name>
</author>
<author>
<name sortKey="Krivulka, Gr" uniqKey="Krivulka G">GR Krivulka</name>
</author>
<author>
<name sortKey="Lifton, Ma" uniqKey="Lifton M">MA Lifton</name>
</author>
<author>
<name sortKey="Kuroda, Mj" uniqKey="Kuroda M">MJ Kuroda</name>
</author>
<author>
<name sortKey="Schmitz, Je" uniqKey="Schmitz J">JE Schmitz</name>
</author>
<author>
<name sortKey="Letvin, Nl" uniqKey="Letvin N">NL Letvin</name>
</author>
<author>
<name sortKey="Caulfield, Mj" uniqKey="Caulfield M">MJ Caulfield</name>
</author>
<author>
<name sortKey="Bett, Aj" uniqKey="Bett A">AJ Bett</name>
</author>
<author>
<name sortKey="Youil, R" uniqKey="Youil R">R Youil</name>
</author>
<author>
<name sortKey="Kaslow, Dc" uniqKey="Kaslow D">DC Kaslow</name>
</author>
<author>
<name sortKey="Emini, Ea" uniqKey="Emini E">EA Emini</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Yang, Zy" uniqKey="Yang Z">ZY Yang</name>
</author>
<author>
<name sortKey="Kong, Wp" uniqKey="Kong W">WP Kong</name>
</author>
<author>
<name sortKey="Huang, Y" uniqKey="Huang Y">Y Huang</name>
</author>
<author>
<name sortKey="Roberts, A" uniqKey="Roberts A">A Roberts</name>
</author>
<author>
<name sortKey="Murphy, Br" uniqKey="Murphy B">BR Murphy</name>
</author>
<author>
<name sortKey="Subbarao, K" uniqKey="Subbarao K">K Subbarao</name>
</author>
<author>
<name sortKey="Nabel, Gj" uniqKey="Nabel G">GJ Nabel</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Yi, Ce" uniqKey="Yi C">CE Yi</name>
</author>
<author>
<name sortKey="Ba, L" uniqKey="Ba L">L Ba</name>
</author>
<author>
<name sortKey="Zhang, L" uniqKey="Zhang L">L Zhang</name>
</author>
<author>
<name sortKey="Ho, Dd" uniqKey="Ho D">DD Ho</name>
</author>
<author>
<name sortKey="Chen, Z" uniqKey="Chen Z">Z Chen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Zeng, Fy" uniqKey="Zeng F">FY Zeng</name>
</author>
<author>
<name sortKey="Chan, Cw" uniqKey="Chan C">CW Chan</name>
</author>
<author>
<name sortKey="Chan, Mn" uniqKey="Chan M">MN Chan</name>
</author>
<author>
<name sortKey="Chen, Jd" uniqKey="Chen J">JD Chen</name>
</author>
<author>
<name sortKey="Chow, Ky" uniqKey="Chow K">KY Chow</name>
</author>
<author>
<name sortKey="Hon, Cc" uniqKey="Hon C">CC Hon</name>
</author>
<author>
<name sortKey="Hui, Kh" uniqKey="Hui K">KH Hui</name>
</author>
<author>
<name sortKey="Li, J" uniqKey="Li J">J Li</name>
</author>
<author>
<name sortKey="Li, Vy" uniqKey="Li V">VY Li</name>
</author>
<author>
<name sortKey="Wang, Cy" uniqKey="Wang C">CY Wang</name>
</author>
<author>
<name sortKey="Wang, Py" uniqKey="Wang P">PY Wang</name>
</author>
<author>
<name sortKey="Guan, Y" uniqKey="Guan Y">Y Guan</name>
</author>
<author>
<name sortKey="Zheng, B" uniqKey="Zheng B">B Zheng</name>
</author>
<author>
<name sortKey="Poon, Ll" uniqKey="Poon L">LL Poon</name>
</author>
<author>
<name sortKey="Chan, Kh" uniqKey="Chan K">KH Chan</name>
</author>
<author>
<name sortKey="Yuen, Ky" uniqKey="Yuen K">KY Yuen</name>
</author>
<author>
<name sortKey="Peiris, Js" uniqKey="Peiris J">JS Peiris</name>
</author>
<author>
<name sortKey="Leung, Fc" uniqKey="Leung F">FC Leung</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Zhang, L" uniqKey="Zhang L">L Zhang</name>
</author>
<author>
<name sortKey="Zhang, F" uniqKey="Zhang F">F Zhang</name>
</author>
<author>
<name sortKey="Yu, W" uniqKey="Yu W">W Yu</name>
</author>
<author>
<name sortKey="He, T" uniqKey="He T">T He</name>
</author>
<author>
<name sortKey="Yu, J" uniqKey="Yu J">J Yu</name>
</author>
<author>
<name sortKey="Yi, Ce" uniqKey="Yi C">CE Yi</name>
</author>
<author>
<name sortKey="Ba, L" uniqKey="Ba L">L Ba</name>
</author>
<author>
<name sortKey="Li, W" uniqKey="Li W">W Li</name>
</author>
<author>
<name sortKey="Farzan, M" uniqKey="Farzan M">M Farzan</name>
</author>
<author>
<name sortKey="Chen, Z" uniqKey="Chen Z">Z Chen</name>
</author>
<author>
<name sortKey="Yuen, Ky" uniqKey="Yuen K">KY Yuen</name>
</author>
<author>
<name sortKey="Ho, D" uniqKey="Ho D">D Ho</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="research-article">
<pmc-dir>properties open_access</pmc-dir>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Appl Microbiol Biotechnol</journal-id>
<journal-id journal-id-type="iso-abbrev">Appl. Microbiol. Biotechnol</journal-id>
<journal-title-group>
<journal-title>Applied Microbiology and Biotechnology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0175-7598</issn>
<issn pub-type="epub">1432-0614</issn>
<publisher>
<publisher-name>Springer Berlin Heidelberg</publisher-name>
<publisher-loc>Berlin/Heidelberg</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">17581748</article-id>
<article-id pub-id-type="pmc">7079952</article-id>
<article-id pub-id-type="publisher-id">1073</article-id>
<article-id pub-id-type="doi">10.1007/s00253-007-1073-y</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Applied Microbial and Cell Physiology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ba</surname>
<given-names>Lei</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yi</surname>
<given-names>Christopher E.</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Linqi</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ho</surname>
<given-names>David D.</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chen</surname>
<given-names>Zhiwei</given-names>
</name>
<address>
<email>zchen@adarc.org</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1">
<institution-wrap>
<institution-id institution-id-type="GRID">grid.134907.8</institution-id>
<institution-id institution-id-type="ISNI">0000000121661519</institution-id>
<institution>Aaron Diamond AIDS Research Center,</institution>
<institution>The Rockefeller University,</institution>
</institution-wrap>
455 1st Avenue, New York, NY 10016 USA</aff>
</contrib-group>
<pub-date pub-type="epub">
<day>21</day>
<month>6</month>
<year>2007</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2007</year>
</pub-date>
<volume>76</volume>
<issue>5</issue>
<fpage>1131</fpage>
<lpage>1136</lpage>
<history>
<date date-type="received">
<day>27</day>
<month>4</month>
<year>2007</year>
</date>
<date date-type="rev-recd">
<day>30</day>
<month>5</month>
<year>2007</year>
</date>
<date date-type="accepted">
<day>1</day>
<month>6</month>
<year>2007</year>
</date>
</history>
<permissions>
<copyright-statement>© Springer-Verlag 2007</copyright-statement>
<license>
<license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p>Severe acute respiratory syndrome (SARS) is caused by a novel coronavirus (CoV), SARS-CoV. In previous studies, we showed that a SARS-CoV spike (S) glycoprotein-based modified vaccinia Ankara (MVA-S) vaccine could induce strong neutralizing antibody (Nab) response which might have played a critical role in protecting Chinese rhesus monkeys from the pathogenic viral challenge. To date, however, it remains unknown what the minimal level of Nab is required to achieve sterile immunity in humans. It is therefore important to explore techniques to maximize the level of Nab response in vivo. Here, we evaluate various vaccination regimens using combinations of DNA-S, MVA-S, and adenovirus type 5 (Ad5-S) vaccines. We show that in vaccinated mice and rabbits, a heterologous MVA-S prime with Ad5-S boost regimen induces the highest and most persistent level of Nab response when compared with other combinations. Interestingly, the initial level of Nab after prime does not necessarily predict the magnitude of the secondary response after the boost. Thus, our data provides a promising optimal regimen for vaccine development in humans against SARS-CoV infection.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>SARS</kwd>
<kwd>SARS-CoV</kwd>
<kwd>MVA</kwd>
<kwd>Ad5</kwd>
<kwd>Vaccine</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer-Verlag 2007</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1" sec-type="introduction">
<title>Introduction</title>
<p>Shortly after the 2003 epidemic, the etiological agent for severe acute respiratory syndrome (SARS) was determined to be SARS coronavirus (SARS-CoV; Drosten et al.
<xref ref-type="bibr" rid="CR9">2003</xref>
; Ksiazek et al.
<xref ref-type="bibr" rid="CR14">2003</xref>
; Kuiken et al.
<xref ref-type="bibr" rid="CR15">2003</xref>
; Peiris et al.
<xref ref-type="bibr" rid="CR20">2003</xref>
). Similar to other viruses in the
<italic>Coronaviridae</italic>
family, SARS-CoV is characterized by its crown-like outer shell comprised primarily of spike (S) glycoproteins, which mediate viral entry by interacting with the host cellular ACE2 receptor (Li et al.
<xref ref-type="bibr" rid="CR16">2003</xref>
,
<xref ref-type="bibr" rid="CR17">2005</xref>
). We, along with other groups, previously showed that high titers of neutralizing antibodies (Nabs) are primarily directed toward the receptor-binding domain (RBD) of the S protein (Chen et al.
<xref ref-type="bibr" rid="CR6">2005</xref>
; He et al.
<xref ref-type="bibr" rid="CR12">2005</xref>
; Yi et al.
<xref ref-type="bibr" rid="CR23">2005</xref>
). Thus, the S protein and its RBD serve as a major viral target for vaccine design (Bukreyev et al.
<xref ref-type="bibr" rid="CR4">2004</xref>
; Chen et al.
<xref ref-type="bibr" rid="CR6">2005</xref>
; Yang et al.
<xref ref-type="bibr" rid="CR22">2004</xref>
).</p>
<p>Multiple forms of SARS vaccines including DNA-S, MVA-S, and Ad5-S have been independently proven to be effective in protecting animals from pathogenic SARS-CoV challenge (Bisht et al.
<xref ref-type="bibr" rid="CR2">2004</xref>
,
<xref ref-type="bibr" rid="CR3">2005</xref>
; Gao et al.
<xref ref-type="bibr" rid="CR10">2003</xref>
; Yang et al.
<xref ref-type="bibr" rid="CR22">2004</xref>
). The success of these studies has resulted in a minimal need for the development of a prime–boost regimen against SARS. To date, however, it remains unknown what the minimal level of Nabs is required to achieve sterile immunity in humans. There are recent evidences that a better protection may require sufficient amount of specific Nabs (Deming et al.
<xref ref-type="bibr" rid="CR8">2006</xref>
; Liu et al.
<xref ref-type="bibr" rid="CR18">2007</xref>
). It is therefore critical to explore techniques to maximize the level of Nab response in vivo. Here, we evaluate prime–boost strategies using various combinations of DNA-S, MVA-S, and Ad5-S to determine which regimen induces the highest and most persistent level of Nab response. We aim to identify an optimal vaccine regimen not only for preventing SARS-CoV infection but also for combating other tough viruses including the human immunodeficiency virus type one (HIV-1).</p>
</sec>
<sec id="Sec2" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="Sec3">
<title>DNA-S and MVA-S constructions</title>
<p>The S gene was originally obtained from SARS-CoV HKU39849, an isolate from Hong Kong (GenBank accession number AY278491; Zeng et al.
<xref ref-type="bibr" rid="CR24">2003</xref>
). Based on the viral genome sequence, we constructed a codon-optimized full-length S gene using synthetic overlapping oligonucleotides (Zhang et al.
<xref ref-type="bibr" rid="CR25">2006</xref>
). The optimized S gene was then cloned into a eukaryotic expression vector pcDNA3.1 under the control of a cytomegalovirus (CMV) promoter (pcDNA3.1-OPT9; Invitrogen, Carlsbad, CA). The pcDNA3.1-OPT9 was used as the DNA-S vaccine. The construction of MVA-S has been previously described (Chen et al.
<xref ref-type="bibr" rid="CR6">2005</xref>
).</p>
</sec>
<sec id="Sec4">
<title>Ad5-S construction</title>
<p>The full-length, codon-optimized SARS S gene was inserted into a recombinant adenovirus-5 vector using BD Adeno-X Expression Systems 2 (BD Biosciences, Palo Alto, CA). Briefly, the full-length S gene from pcDNA3.1-OPT9 was cloned into the pDNR-CMV donor vector and recombined with pLP-Adeno-X-CMV. Pac I-digested recombinant adenoviral vector was transfected into HEK-293 (ATCC, CRL-1573), and supernatant was collected 3–4 days posttransfection. This supernatant was used to infect a large culture of HEK-293 cells for large-scale production. Recombinant adenovirus (Ad5-S) was purified using two successive CsCl gradient (first:
<italic>d</italic>
 = 1.25 g/ml and
<italic>d</italic>
 = 1.4 g/ml; second:
<italic>d</italic>
 = 1.34 g/ml) centrifugation spins at 35,000 rpm at 18°C. Concentrated Ad5-S was dialyzed in phosphate buffered saline (PBS) and stored with glycerol at −150°C.</p>
</sec>
<sec id="Sec5">
<title>Animal immunizations</title>
<p>Six- to eight-week-old female BALB/c mice (Charles River Laboratories) were immunized by intramuscular (i.m.) injection of DNA-S, MVA-S, or Ad5-S. The dose of each vaccine was 200 μg of DNA-S (in 200-μl saline), 5 × 10
<sup>7</sup>
50% tissue culture infective dose (TCID
<sub>50</sub>
) of MVA-S or 5 × 10
<sup>7</sup>
TCID
<sub>50</sub>
of Ad5-S. We collected blood samples 2 weeks after the first immunization. Four weeks after the prime, we boosted several groups of primed mice (three mice per group) with DNA-S, MVA-S, or Ad5-S according to various regimens. The mice were killed, and their blood samples were used for analysis 2 weeks after the second immunization. New Zealand white rabbits (Charles River Laboratories) were immunized by i.m. injection of MVA-S or Ad5-S. Three rabbits were immunized with 5 × 10
<sup>8</sup>
TCID
<sub>50</sub>
of MVA-S, and another six were immunized with 5 × 10
<sup>8</sup>
TCID
<sub>50</sub>
of Ad5-S on day 0. Four weeks later, Three MVA-S-primed animals were boosted with the same dose of Ad5-S, whereas the rest received MVA-S. Blood samples were collected 3 weeks after the first immunization and 2, 6, 9, and 16 weeks after the second immunization. All animal experiments were approved by and conducted in the Laboratory Animal Research Center at The Rockefeller University.</p>
</sec>
<sec id="Sec6">
<title>Neutralization assay</title>
<p>A pseudovirus-based neutralization assay was established to determine the humoral immune responses against SARS-CoV (Chen et al.
<xref ref-type="bibr" rid="CR6">2005</xref>
). Briefly, the neutralizing activity of heat-inactivated sera (56°C, 30 min) was determined by mixing 10 ng of pseudovirus (in 30 μl) with diluted serum (in 30 μl) at 37°C for 1 h. The SARS-pseudovirus was generated by cotransfecting 293 T cells with two plasmids pcDNA3.1-OPT9 and pNL4-3Luc
<sup>+</sup>
Env
<sup></sup>
Vpr
<sup></sup>
carrying the optimized S gene and a HIV-1 backbone, respectively. After neutralization, the mixture was combined with 16-ng polybrene (in 40-μl medium) and added to HEK293T-ACE2 (1,000 cells per well in 100 μl). Cells were washed with PBS and lysed (1× Cell Culture Lysis Reagent, Promega) 56–72 h after infection. Luciferase intensity was measured and the percentage of neutralization was calculated.</p>
</sec>
</sec>
<sec id="Sec7" sec-type="results">
<title>Results</title>
<sec id="Sec8">
<title>DNA-S, MVA-S, and Ad5-S prime–boost immunizations in mice</title>
<p>To determine the Nab response to various prime–boost immunizations, we constructed separate DNA-S, MVA-S, and Ad5-S vaccines containing the full-length SARS-CoV S gene. We immunized three groups of BALB/c mice with either DNA-S (nine mice), MVA-S (six mice), or Ad5-S (six mice). Sera were collected 3 weeks after the first immunization, sequentially diluted (30- to 24,300-fold) and measured for the level of Nab activity against the SARS-pseudovirus. As shown in Fig. 
<xref rid="Fig1" ref-type="fig">1</xref>
, priming with Ad5-S elicited the highest level of Nabs against SARS-pseudovirus. MVA-S induces about tenfold (IC
<sub>50</sub>
) lower levels of Nabs than Ad5-S, with DNA-S being the lowest (Fig. 
<xref rid="Fig1" ref-type="fig">1</xref>
). Therefore, the live vector Ad5 may offer some advantages for inducing the highest level of Nab response after one immunization. Interestingly, this initial level of Nab after prime does not necessarily predict the magnitude of the secondary response after the boost.
<fig id="Fig1">
<label>Fig. 1</label>
<caption>
<p>Nab response in mice that were primed with DNA-S, MVA-S, or Ad5-S vaccines. Three mice as a group were tested for each vaccine. The average values of each test group and the standard error bars are presented. This neutralization experiment was repeated three times with consistent results obtained</p>
</caption>
<graphic xlink:href="253_2007_1073_Fig1_HTML" id="MO1"></graphic>
</fig>
</p>
<p>Four weeks after the first immunization, the mice were boosted with DNA-S (D), MVA-S (M), or Ad5-S (A). Sera were collected 2 weeks after the boost, sequentially diluted (200- to 145,800-fold), and measured for the level of Nab activity against the SARS-pseudovirus. The second immunization has boosted the Nab response in all groups. When we compared the regimen effects based on the IC
<sub>50</sub>
and IC
<sub>90</sub>
values, we found that a DNA-S prime, DNA-S boost (DD) regimen induced the lowest level of Nab activity (Fig. 
<xref rid="Fig2" ref-type="fig">2</xref>
). On the other hand, priming with MVA-S and boosting with Ad5-S (MA) produced the highest level of Nabs, which is over tenfold greater than the DD animals (Fig. 
<xref rid="Fig2" ref-type="fig">2</xref>
). We detected relatively lower levels of Nabs in mice primed with MVA-S or DNA-S and boosted with MVA-S (MM, DM) than MA animals (Fig. 
<xref rid="Fig2" ref-type="fig">2</xref>
). Surprisingly, mice primed with Ad5-S and boosted with either Ad5-S or MVA-S (AA, AM) showed levels above the DD regimen, but below the rest (Fig. 
<xref rid="Fig2" ref-type="fig">2</xref>
). This finding indicates the importance of heterologous MVA-S prime and Ad5-S boost regimen for inducing the substantial level of Nab response. The use of this regimen also offers an advantage to overcome the problems related to vaccine-induced immune response against these live viral vectors.
<fig id="Fig2">
<label>Fig. 2</label>
<caption>
<p>Nab response in mice after the boost immunization with DNA-S, MVA-S, or Ad5-S vaccines. The letters present different combination of vaccinations:
<italic>DD</italic>
for DNA-S prime and DNA-S boost;
<italic>MM</italic>
for MVA-S prime and MVA-S boost;
<italic>AA</italic>
for Ad5-S prime and Ad5-S boost;
<italic>DM</italic>
for DNA-S prime and MVA-S boost;
<italic>AM</italic>
for Ad5-S prime and MVA-S boost;
<italic>MA</italic>
for MVA-S prime and AD5-S boost; and
<italic>DA</italic>
for DNA-S prime and AD5-S boost. Three mice as a group were tested for each vaccine. The average values of each test group and the standard error bars are presented. This neutralization experiment was repeated three times with consistent results obtained</p>
</caption>
<graphic xlink:href="253_2007_1073_Fig2_HTML" id="MO2"></graphic>
</fig>
</p>
</sec>
<sec id="Sec9">
<title>MVA-S and Ad5-S prime–boost immunizations in rabbits</title>
<p>To determine whether our findings in mice can be reproduced in a different animal species, we primed nine New Zealand white rabbits with either Ad5-S (six rabbits) or MVA-S (three rabbits). Thirty days after the first immunization, we measured the presence of Nabs to SARS in each rabbit serum. Collected serum was sequentially diluted 600- to 437,400-fold and analyzed for neutralizing activity against the SARS-pseudovirus. In the six rabbits immunized with Ad5-S, we measured an average IC
<sub>50</sub>
of greater than a 54,000-fold serum dilution (Fig. 
<xref rid="Fig3" ref-type="fig">3</xref>
). We observed a significantly greater level of Nabs (15-fold) in rabbits immunized with Ad5-S than in rabbits immunized with MVA-S, which showed an average IC
<sub>50</sub>
of 3,600 (Fig. 
<xref rid="Fig3" ref-type="fig">3</xref>
). Therefore, similar to mice, we showed that, after one immunization, we can induce a greater antibody response using Ad5-S, rather than MVA-S, as a viral vector vaccine.
<fig id="Fig3">
<label>Fig. 3</label>
<caption>
<p>Nab response in rabbits that were primed with MVA-S or Ad5-S vaccines. Three rabbits as a group were tested for each vaccine. The average values of each test group and the standard error bars are presented. This neutralization experiment was repeated three times with consistent results obtained</p>
</caption>
<graphic xlink:href="253_2007_1073_Fig3_HTML" id="MO3"></graphic>
</fig>
</p>
<p>After measuring the Nab response to priming, we boosted the rabbits with either Ad5-S or MVA-S. Three of the rabbits primed with Ad5-S were boosted with MVA-S (AM), whereas the remaining three were boosted with another injection of Ad5-S (AA). The three rabbits primed with MVA-S were boosted with Ad5-S (MA). Two weeks after the second injection, we collected the serum samples, sequentially diluted (1,800- to 1,312,200-fold) and measured it for the level of Nab activity against the SARS-pseudovirus. Rabbits primed with Ad5-S and boosted with either Ad5-S (AA) or MVA-S (AM) showed comparable levels of Nab activity (Fig. 
<xref rid="Fig4" ref-type="fig">4</xref>
). However, in rabbits primed with MVA-S and boosted with Ad5-S (MA), we observed a significantly higher level of Nab activity compared with AM and AA rabbits (Fig. 
<xref rid="Fig4" ref-type="fig">4</xref>
). MA rabbits had about five- to sevenfold higher Nab response in serum Nab IC
<sub>50</sub>
and IC
<sub>90</sub>
after heterologous boosting than the AA animals. In comparison to the boost effects found in both AM and AA rabbits, heterologous boosting with Ad5-S likely determines the extent of the secondary Nab response in MA animals.
<fig id="Fig4">
<label>Fig. 4</label>
<caption>
<p>Nab response in rabbits after the boost immunization with MVA-S or Ad5-S vaccines. The letters present different combination of vaccinations:
<italic>AM</italic>
for Ad5-S prime and MVA-S boost regimen;
<italic>AA</italic>
for Ad5-S prime and Ad5-S boost regimen; and
<italic>MA</italic>
for MVA-S prime and AD5-S boost regimen. Three rabbits as a group were tested for each regimen. The average values of each test group and the standard error bars are presented. This Nab experiment was repeated three times with consistent results obtained</p>
</caption>
<graphic xlink:href="253_2007_1073_Fig4_HTML" id="MO4"></graphic>
</fig>
</p>
</sec>
<sec id="Sec10">
<title>Prolonged Nab activity in rabbits with MVA-S prime and Ad5-S boost immunizations</title>
<p>Over a prolonged time course, we continued to observe a greater Nab response in rabbits primed with MVA-S and boosted with Ad5-S. In addition to the measurements 2 weeks after boosting, we measured the Nab response 6, 9, and 16 weeks after boosting. Based on IC
<sub>50</sub>
extrapolations, we showed that the levels of Nab in MA rabbits remained significantly greater for as long as 4 months after the booster (Fig. 
<xref rid="Fig5" ref-type="fig">5</xref>
). In fact, the IC
<sub>50</sub>
levels that initially rose to a fourfold increase in MA rabbits over AA and AM rabbits 2 weeks after the boost remained two to three times greater over the extended measurements (Fig. 
<xref rid="Fig5" ref-type="fig">5</xref>
). The same can be observed with IC
<sub>90</sub>
serum Nab levels. AM rabbits only showed an average IC
<sub>90</sub>
increase of twofold 14 days after the boost, with levels dropping back to what we observed upon Ad5-S priming (Fig. 
<xref rid="Fig5" ref-type="fig">5</xref>
). AA rabbits failed to show an increase in IC
<sub>90</sub>
serum Nab levels after the prime. MA rabbits, on the other hand, showed a five- to sevenfold increase over AM and AA rabbit IC
<sub>90</sub>
Nab levels 2 weeks after the boost, with a sustained two- to threefold increase over 6, 9, and 16 weeks. Therefore, heterologous MVA-S prime and Ad5-S boost are shown to be the most immunogenic for eliciting a prolonged Nab immune response against SARS-CoV.
<fig id="Fig5">
<label>Fig. 5</label>
<caption>
<p>Persistent Nab response after the boost immunization with MVA-S or Ad5-S vaccines in rabbits. The x-axis represents the time following boost immunization. The y-axis indicates the serum dilution titer when IC
<sub>50</sub>
(
<bold>a</bold>
) or IC
<sub>90</sub>
(
<bold>b</bold>
) was achieved. Three rabbits as a group were tested for each vaccine regimen. The average values of each test group and the standard error bars are presented. The neutralization assay was repeated three times with consistent results obtained</p>
</caption>
<graphic xlink:href="253_2007_1073_Fig5_HTML" id="MO5"></graphic>
</fig>
</p>
</sec>
</sec>
<sec id="Sec11" sec-type="discussion">
<title>Discussion</title>
<p>With the emergence of the SARS epidemic in 2003, much attention has been focused on developing an effective vaccine to combat the threat of recurrence. Previously, we showed the promise of using the MVA-S to protect against a pathogenic SARS-CoV challenge in Chinese rhesus monkeys (Chen et al.
<xref ref-type="bibr" rid="CR6">2005</xref>
). Here, we studied various prime–boost regimens in both mice and rabbits to determine the optimal conditions required to induce the greatest, long-lasting Nab response against SARS-CoV. Beginning with mice, priming with the nonreplication competent Ad5-S initiated the highest level of serum Nabs against the SARS-CoV virus (Fig. 
<xref rid="Fig1" ref-type="fig">1</xref>
). Both DNA-S and MVA-S priming showed significantly lower levels of Nabs induced. This primary Nab response, however, did not predict the effectiveness of the priming. Boosting the Ad5-S-primed mice with either MVA-S or Ad5-S resulted in an increase in serum Nabs. Interestingly, this increased level of Nab response was significantly lower than that of the MVA-S-primed, Ad5-S-boosted mice (Fig. 
<xref rid="Fig2" ref-type="fig">2</xref>
). This finding indicates the importance of heterologous MVA-S prime and Ad5-S boost regimen for inducing the substantial level of Nab response. The use of this regimen also offers an advantage to overcome the problems related to vaccine-induced immune response against these live viral vectors.</p>
<p>Similar to our findings in mice, we observed significantly lower levels of Nabs in rabbits primed with MVA-S, compared to Ad5-S (Fig. 
<xref rid="Fig3" ref-type="fig">3</xref>
). Upon boosting Ad5-S-primed rabbits with either MVA-S or Ad5-S, the serum IC
<sub>50</sub>
Nab levels increased above twofold in Ad5-S-primed and MVA-S-boosted animals and less than twofold for Ad5-S-primed and Ad5-S-boosted animals 2 weeks after boosting. However, MVA-S-primed and Ad5-S-boosted rabbits reached a significantly higher serum Nab IC
<sub>50</sub>
titer 2 weeks after boosting. We suspect that homologous Ad5-S (or MVA-S) prime and boost failed to reach substantial levels, because a preexisting immunity from the priming probably results in expedited vector interference or clearance. As for the heterologous vaccination regimen, the underlined mechanism for why priming with MVA-S is superior to Ad5-S is of interest for further investigation. It is possible that MVA-S is much better than Ad5-S for priming the memory B cells, which are essential for boosting the potent Nab response. Moreover, a high level of Nab response generated by Ad5-S priming does not necessarily indicate a similar level of memory response is simultaneously induced.</p>
<p>Over 16 weeks of observation, we found a significantly higher level (two- to threefold serum IC
<sub>50</sub>
titer) of serum Nabs in MVA-S-primed and Ad5-S-boosted rabbits compared with animals that received other regimens. Furthermore, Nab measurements based on serum IC
<sub>90</sub>
titer show an even more apparent disparity. The Ad5-S-primed and Ad5-S-boosted rabbits showed little beneficial effects with a homologous boost, whereas the Ad5-S-primed and MVA-S-boosted rabbits showed a rapid twofold increase, with an IC
<sub>90</sub>
returning to levels observed just after priming. MVA-S-primed and Ad5-S-boosted rabbits, however, had a much greater IC
<sub>90</sub>
increase after heterologous boosting, with persistently two- to threefold higher levels 16 weeks later. Clearly, rabbits primed with MVA-S and boosted with Ad5-S show a substantial advantage over other immunization regimens tested in triggering a persistent vaccine-induced Nab response of high quality.</p>
<p>The quest to optimize vaccine vector delivery systems and prime–boost strategies is a subject often raised with HIV-1 vaccine design. Data generated in nonhuman primates has demonstrated that a DNA prime-MVA boost regimen was superior to either vaccines used alone for inducing high levels of protective cell-mediated response against pathogenic simian immunodeficiency virus (SIV) or human/simian immunodeficiency virus (SHIV; Amara et al.
<xref ref-type="bibr" rid="CR1">2001</xref>
; Horton et al.
<xref ref-type="bibr" rid="CR13">2002</xref>
). This strategy has also been proven to be effective against influenza and malaria (Degano et al.
<xref ref-type="bibr" rid="CR7">1999</xref>
; McConkey et al.
<xref ref-type="bibr" rid="CR19">2003</xref>
). Similarly, a DNA prime-Ad5 boost regimen also showed great efficacy in nonhuman primates against a SHIV challenge (Shiver et al.
<xref ref-type="bibr" rid="CR21">2002</xref>
). To date, a few studies have evaluated the regimens using live viral vectors. Among them, boosting of an adenovirus-primed immune response with a MVA vaccine led to enhanced immunogenicity and substantial protective efficacy in mice against malaria and SHIV infection (Casimiro et al.
<xref ref-type="bibr" rid="CR5">2004</xref>
; Gilbert et al.
<xref ref-type="bibr" rid="CR11">2002</xref>
). In fact, the MVA prime-adenovirus boost regimen scored second best in the study for inducing protective immunity (Gilbert et al.
<xref ref-type="bibr" rid="CR11">2002</xref>
). Here, we demonstrate for the first time that the heterologous MVA-S prime and Ad5-S boost regimen offers great advantages for inducing Nabs against SARS-CoV. This finding is useful to study AIDS vaccine design because it is recognized that the cell-mediated response alone is not sufficient to achieve sterile immunity against HIV-1. It is of great interest to determine whether this regimen would improve the immunogenicity profile of some promising, yet weak HIV-1 immunogens aimed at inducing Nabs.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>We thank the National Heart, Lung and Blood Institute (R01 HL080211-02 to Z.C.) and Aaron Diamond Fund for financial support. Lei Ba and Christopher E. Yi made equal contributions.</p>
</ack>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amara</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Villinger</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Altman</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Lydy</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>O’Neil</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Staprans</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Montefiori</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Herndon</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Wyatt</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Candido</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Kozyr</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Earl</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Grimm</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Hulsey</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McClure</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>McNicholl</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>HL</given-names>
</name>
</person-group>
<article-title>Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine</article-title>
<source>Science</source>
<year>2001</year>
<volume>292</volume>
<issue>5514</issue>
<fpage>69</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1126/science.1058915</pub-id>
<pub-id pub-id-type="pmid">11393868</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bisht</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bukreyev</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Subbarao</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2004</year>
<volume>101</volume>
<issue>17</issue>
<fpage>6641</fpage>
<lpage>6646</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0401939101</pub-id>
<pub-id pub-id-type="pmid">15096611</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bisht</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Subbarao</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein</article-title>
<source>Virology</source>
<year>2005</year>
<volume>334</volume>
<issue>2</issue>
<fpage>160</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.1016/j.virol.2005.01.042</pub-id>
<pub-id pub-id-type="pmid">15780866</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bukreyev</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lamirande</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>Buchholz</surname>
<given-names>UJ</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>LN</given-names>
</name>
<name>
<surname>Elkins</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>St Claire</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Subbarao</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>PL</given-names>
</name>
</person-group>
<article-title>Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS</article-title>
<source>Lancet</source>
<year>2004</year>
<volume>363</volume>
<issue>9427</issue>
<fpage>2122</fpage>
<lpage>2127</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(04)16501-X</pub-id>
<pub-id pub-id-type="pmid">15220033</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casimiro</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Bett</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>R</given-names>
</name>
<name>
<surname>McKelvey</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chastain</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gurunathan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Emini</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Shiver</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors</article-title>
<source>J Virol</source>
<year>2004</year>
<volume>78</volume>
<issue>20</issue>
<fpage>11434</fpage>
<lpage>11438</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.78.20.11434-11438.2004</pub-id>
<pub-id pub-id-type="pmid">15452269</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ba</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>He</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Gettie</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Farzan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yuen</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>DD</given-names>
</name>
</person-group>
<article-title>Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region</article-title>
<source>J Virol</source>
<year>2005</year>
<volume>79</volume>
<issue>5</issue>
<fpage>2678</fpage>
<lpage>2688</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.79.5.2678-2688.2005</pub-id>
<pub-id pub-id-type="pmid">15708987</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Degano</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hannan</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>AV</given-names>
</name>
</person-group>
<article-title>Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models</article-title>
<source>Vaccine</source>
<year>1999</year>
<volume>18</volume>
<issue>7–8</issue>
<fpage>623</fpage>
<lpage>632</lpage>
<pub-id pub-id-type="doi">10.1016/S0264-410X(99)00278-9</pub-id>
<pub-id pub-id-type="pmid">10547421</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deming</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sheahan</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Heise</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yount</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Suthar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Harkema</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Whitmore</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pickles</surname>
<given-names>R</given-names>
</name>
<name>
<surname>West</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Donaldson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Curtis</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Baric</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants</article-title>
<source>PLoS Med</source>
<year>2006</year>
<volume>3</volume>
<issue>12</issue>
<fpage>e525</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pmed.0030525</pub-id>
<pub-id pub-id-type="pmid">17194199</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drosten</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Preiser</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Gunther</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Doerr</surname>
<given-names>HW</given-names>
</name>
</person-group>
<article-title>Severe acute respiratory syndrome: identification of the etiological agent</article-title>
<source>Trends Mol Med</source>
<year>2003</year>
<volume>9</volume>
<issue>8</issue>
<fpage>325</fpage>
<lpage>327</lpage>
<pub-id pub-id-type="doi">10.1016/S1471-4914(03)00133-3</pub-id>
<pub-id pub-id-type="pmid">12928032</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Tamin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Soloff</surname>
<given-names>A</given-names>
</name>
<name>
<surname>D’Aiuto</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Nwanegbo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Robbins</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Bellini</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Barratt-Boyes</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gambotto</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Effects of a SARS-associated coronavirus vaccine in monkeys</article-title>
<source>Lancet</source>
<year>2003</year>
<volume>362</volume>
<issue>9399</issue>
<fpage>1895</fpage>
<lpage>1896</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(03)14962-8</pub-id>
<pub-id pub-id-type="pmid">14667748</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilbert</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hannan</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Plebanski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sinden</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>AV</given-names>
</name>
</person-group>
<article-title>Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes</article-title>
<source>Vaccine</source>
<year>2002</year>
<volume>20</volume>
<issue>7–8</issue>
<fpage>1039</fpage>
<lpage>1045</lpage>
<pub-id pub-id-type="doi">10.1016/S0264-410X(01)00450-9</pub-id>
<pub-id pub-id-type="pmid">11803063</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies</article-title>
<source>J Immunol</source>
<year>2005</year>
<volume>174</volume>
<issue>8</issue>
<fpage>4908</fpage>
<lpage>4915</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.174.8.4908</pub-id>
<pub-id pub-id-type="pmid">15814718</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horton</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>TU</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Vielhuber</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fuller</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Shipley</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fuller</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Kunstman</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Sutter</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Montefiori</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Erfle</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Desrosiers</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Picker</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Wolinsky</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Allison</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Watkins</surname>
<given-names>DI</given-names>
</name>
</person-group>
<article-title>Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239</article-title>
<source>J Virol</source>
<year>2002</year>
<volume>76</volume>
<issue>14</issue>
<fpage>7187</fpage>
<lpage>7202</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.76.14.7187-7202.2002</pub-id>
<pub-id pub-id-type="pmid">12072518</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ksiazek</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Erdman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Goldsmith</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Zaki</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Peret</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Emery</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Urbani</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Comer</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Rollin</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Dowell</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Humphrey</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Shieh</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Guarner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Paddock</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Rota</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fields</surname>
<given-names>B</given-names>
</name>
<name>
<surname>DeRisi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>LeDuc</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Bellini</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>LJ</given-names>
</name>
</person-group>
<article-title>A novel coronavirus associated with severe acute respiratory syndrome</article-title>
<source>N Engl J Med</source>
<year>2003</year>
<volume>348</volume>
<issue>20</issue>
<fpage>1953</fpage>
<lpage>1966</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa030781</pub-id>
<pub-id pub-id-type="pmid">12690092</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuiken</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fouchier</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Schutten</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rimmelzwaan</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>van Amerongen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>van Riel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Laman</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>de Jong</surname>
<given-names>T</given-names>
</name>
<name>
<surname>van Doornum</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Tam</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Zambon</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Gopal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Drosten</surname>
<given-names>C</given-names>
</name>
<name>
<surname>van der Werf</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Escriou</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Manuguerra</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Stohr</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Peiris</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Osterhaus</surname>
<given-names>AD</given-names>
</name>
</person-group>
<article-title>Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome</article-title>
<source>Lancet</source>
<year>2003</year>
<volume>362</volume>
<issue>9380</issue>
<fpage>263</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(03)13967-0</pub-id>
<pub-id pub-id-type="pmid">12892955</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Vasilieva</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sui</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Berne</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Somasundaran</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Luzuriaga</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Greenough</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Choe</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Farzan</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title>
<source>Nature</source>
<year>2003</year>
<volume>426</volume>
<issue>6965</issue>
<fpage>450</fpage>
<lpage>454</lpage>
<pub-id pub-id-type="doi">10.1038/nature02145</pub-id>
<pub-id pub-id-type="pmid">14647384</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Farzan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>SC</given-names>
</name>
</person-group>
<article-title>Structure of SARS coronavirus spike receptor-binding domain complexed with receptor</article-title>
<source>Science</source>
<year>2005</year>
<volume>309</volume>
<issue>5742</issue>
<fpage>1864</fpage>
<lpage>1868</lpage>
<pub-id pub-id-type="doi">10.1126/science.1116480</pub-id>
<pub-id pub-id-type="pmid">16166518</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Ba</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus</article-title>
<source>J Virol</source>
<year>2007</year>
<volume>81</volume>
<issue>9</issue>
<fpage>4694</fpage>
<lpage>4700</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.02389-06</pub-id>
<pub-id pub-id-type="pmid">17314167</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McConkey</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Reece</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Moorthy</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dunachie</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Butcher</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Vuola</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Blanchard</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Gothard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Watkins</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hannan</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Everaere</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kester</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Heppner</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Pathan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Flanagan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Arulanantham</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Peto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sinden</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>AV</given-names>
</name>
</person-group>
<article-title>Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans</article-title>
<source>Nat Med</source>
<year>2003</year>
<volume>9</volume>
<issue>6</issue>
<fpage>729</fpage>
<lpage>735</lpage>
<pub-id pub-id-type="doi">10.1038/nm881</pub-id>
<pub-id pub-id-type="pmid">12766765</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peiris</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Poon</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yam</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Nicholls</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yee</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Cheung</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>VC</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Tsang</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Yung</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>TK</given-names>
</name>
<name>
<surname>Yuen</surname>
<given-names>KY</given-names>
</name>
</person-group>
<article-title>Coronavirus as a possible cause of severe acute respiratory syndrome</article-title>
<source>Lancet</source>
<year>2003</year>
<volume>361</volume>
<issue>9366</issue>
<fpage>1319</fpage>
<lpage>1325</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(03)13077-2</pub-id>
<pub-id pub-id-type="pmid">12711465</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shiver</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Casimiro</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>ZQ</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Trigona</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Dubey</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Handt</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Schleif</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Freed</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Persaud</surname>
<given-names>NV</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Punt</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Heidecker</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>VR</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Joyce</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Grimm</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Keller</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Kresock</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Mach</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Troutman</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Isopi</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Bohannon</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Volkin</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Montefiori</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Miura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krivulka</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Lifton</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Kuroda</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Letvin</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Caulfield</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bett</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Youil</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kaslow</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Emini</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity</article-title>
<source>Nature</source>
<year>2002</year>
<volume>415</volume>
<issue>6869</issue>
<fpage>331</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="doi">10.1038/415331a</pub-id>
<pub-id pub-id-type="pmid">11797011</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>ZY</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Subbarao</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nabel</surname>
<given-names>GJ</given-names>
</name>
</person-group>
<article-title>A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice</article-title>
<source>Nature</source>
<year>2004</year>
<volume>428</volume>
<issue>6982</issue>
<fpage>561</fpage>
<lpage>564</lpage>
<pub-id pub-id-type="doi">10.1038/nature02463</pub-id>
<pub-id pub-id-type="pmid">15024391</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yi</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Ba</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain</article-title>
<source>J Virol</source>
<year>2005</year>
<volume>79</volume>
<issue>18</issue>
<fpage>11638</fpage>
<lpage>11646</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.79.18.11638-11646.2005</pub-id>
<pub-id pub-id-type="pmid">16140741</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>FY</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Hon</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>VY</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>PY</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Poon</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Yuen</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Peiris</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>FC</given-names>
</name>
</person-group>
<article-title>The complete genome sequence of severe acute respiratory syndrome coronavirus strain HKU-39849 (HK-39)</article-title>
<source>Exp Biol Med (Maywood)</source>
<year>2003</year>
<volume>228</volume>
<issue>7</issue>
<fpage>866</fpage>
<lpage>873</lpage>
<pub-id pub-id-type="doi">10.1177/15353702-0322807-13</pub-id>
<pub-id pub-id-type="pmid">12876307</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>He</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Ba</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Farzan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Yuen</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals</article-title>
<source>J Med Virol</source>
<year>2006</year>
<volume>78</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1002/jmv.20499</pub-id>
<pub-id pub-id-type="pmid">16299724</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000264  | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000264  | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     
   |texte=   
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021